Across TCGA pan-cancer cohorts, PLAAT5 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated PLAAT5 data layer compared with 25 for mass-spec protein.
The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher PLAAT5 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated PLAAT5 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.
SKCM and UCEC are the cancer types where PLAAT5 Mutation most reproducibly stratifies survival.